Sarclisa + KRd significantly improved rate of MRD negativity in transplant-eligible patients with newly diagnosed multiple myeloma vs. KRd alone December 12, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
Abecma Approved in Earlier Lines of Therapy for Patients with R/R Multiple Myeloma in Japan December 11, 2023
Sarclisa Ph 3 trial met primary endpoint of PFS in patients with newly diagnosed multiple myeloma not eligible for transplant December 11, 2023
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma December 11, 2023
Positive results from DREAMM-7 head-to-head Ph 3 trial for Blenrep in R/R multiple myeloma announced December 4, 2023
Karyopharm and BMS to Evaluate CC- 92480 Mezigdomide + Selinexor in Patients with R/R Multiple Myeloma November 7, 2023
First Patient dosed in Landmark STAR-LLD Lenalidomide Ph 1b Trial in Multiple Myeloma October 11, 2023
FAILED TRIAL: Ph 3 CANOVA Study of Venetoclax in Patients with RRMM failed to meet primary endpoint of PFS improvement October 3, 2023
Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent CRR reported October 3, 2023
FDA Approves TALVEY™ (talquetamab-tgvs) for the Treatment of Patients with Heavily Pretreated Multiple Myeloma August 16, 2023
FDA clears IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma August 2, 2023
Positive CHMP Opinions for TALVEY (talquetamab) and TECVAYLI (teclistamab) for the Treatment of Patients with R/R Multiple Myeloma July 27, 2023
Positive final KappaMab Ph2b study results in in kappa-type R/R multiple myeloma patients announced July 12, 2023
K36 Therapeutics Announces $70M Series B Financing to Fund Clinical Proof of Concept of KTX-1001 for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14) July 5, 2023
